RecruitingNot ApplicableNCT05934084

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors: A Randomized Non-pharmacological Clinical Trial By The Fondazione Italiana Linfomi (FIL)

Sponsor

Fondazione Italiana Linfomi - ETS

Enrollment

552 participants

Start Date

Feb 26, 2024

Study Type

INTERVENTIONAL

Conditions

Classical Hodgkin Lymphoma

Summary

This is a prospective randomized open-label, multicenter, 2-arm study to assess the role of healthy LifeStyle implemented Survivorship Care Plan (LS-SCP) in modifying the Quality of Life (QoL) in a population of long-term lymphoma survivors (in remission for a minimum 3 years since the last treatment and a maximum of 10 years).

Eligibility

Min Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This study is developing and testing a survivorship care plan for young adults who were treated for lymphoma (a blood cancer) and are now in remission. The plan focuses on lifestyle changes to reduce long-term health risks caused by cancer treatment, such as heart disease. **You may be eligible if...** - You were aged 18–50 when you received your first lymphoma treatment - You were diagnosed with Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), or primary mediastinal large B-cell lymphoma (PMBCL) - You completed first-line chemotherapy and are in complete remission - You have been in remission for at least 3 years but no more than 10 years - You received a meaningful cumulative dose of the chemotherapy drug doxorubicin **You may NOT be eligible if...** - Your cancer has relapsed or you are not in complete remission - You were treated at a younger or older age than the study range - You received a different type of initial chemotherapy than the listed regimens Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALLifestyles Implemented-Survivorship Care Plan (LS-SCP)

Patients in the experimental arm will follow the planned intervention (Survivorship Care Plan (SCP), nutritional plan, physical activity) for 6 months. A bi-monthly automatic call to assess the compliance at the experimental arm (LS-SCP, Lifestyles implemented-Survivorship Care Plan) will be performed.

Locations(40)

Ancona - AOU Ospedali Riuniti - Clinica di Ematologia

Ancona, Ancona, Italy

Aviano - IRCCS Centro di Riferimento Oncologico di Aviano - Divisione di Oncologia e dei Tumori immuto-correlati

Aviano, Aviano, Italy

Istituto Tumori Bari Giovanni Paolo II, U.O. di Ematologia e Terapia Cellulare

Bari, Bari, Italy

Ospedale S. Martino - UOC Oncologia

Belluno, Belluno, Italy

Ospedale "Monsignor Raffaele Dimiccoli" - Ematologia

Barletta, Italy

Ospedale Centrale di Bolzano - Divisione di Ematologia e T.M.O.

Bolzano, Italy

ASST Spedali Civili di Brescia - Ematologia

Brescia, Italy

Ospedale Antonio Perrino - U.O. Ematologia e Trapianti di Midollo

Brindisi, Italy

PO Sant'Elia ASP Caltanisetta - UOC Ematologia

Caltanissetta, Italy

Arnas Nuovo Ospedale Garibaldi Nesima - U.O.C. Ematologia

Catania, Italy

Azienda Ospedaliera Universitaria Policlinico - S. Marco - UOC di Emtologia

Catania, Italy

Ospedale Generale di zona Valduce - Oncoematologia

Como, Italy

Azienda Ospedaliera Universitaria Careggi - Unitа funzionale di Ematologia

Florence, Italy

Ospedale Vito Fazzi - Ematologia

Lecce, Italy

ASST Ovest Milanese - Legnano - U.O.C. Ematologia Ospedale Civile di Legnano

Legnano, Italy

AOU G. Martino - U.O.C. Ematologia

Messina, Italy

ASST Grande Ospedale Metropolitano Niguarda - SC Ematologia

Milan, Italy

IEO Istitito Europeo di Oncologia - Divisione Ematoncologia

Milan, Italy

Ospedale Maggiore Policlinico - Fondazione IRCCS Ca Granda - Ematologia

Milan, Italy

Azienda Ospedaliero-Universitaria Policlinico di Modena - U.O. Oncologia

Modena, Italy

AOU Maggiore della Caritа di Novara - SCDU Ematologia

Novara, Italy

AOU di Padova - Ematologia

Padova, Italy

I.R.C.C.S. Istituto Oncologico Veneto - Oncologia 1

Padova, Italy

Presidio ospedaliero "A. TORTORA" - U.O. Onco-ematologia

Pagani, Italy

AOU Policlinico Giaccone - Ematologia

Palermo, Italy

P.O. Spirito Santo di Pescara - UOS Dipartimentale - Centro di diagnosi e Terapia dei linfomi

Pescara, Italy

Ospedale Guglielmo da Saliceto - U.O.Ematologia

Piacenza, Italy

AOU Pisana - U.O. Ematologia

Pisa, Italy

A.O.R. "San Carlo" - U.O. Ematologia

Potenza, Italy

Azienda Unità Sanitaria Locale-IRCCS - Arcispedale Santa Maria Nuova - Ematologia

Reggio Emilia, Italy

Ospedale degli Infermi di Rimini - U.O. di Ematologia

Rimini, Italy

AO Sant'Andrea - Ematologia

Roma, Italy

Ospedale S. Eugenio - UOC Ematologia

Roma, Italy

Policlinico Tor Vergata - Ematologia

Roma, Italy

Policlinico Universitario Campus Bio-Medico - Ematologia - Trapianto cellule staminali - Medicina Trasfusionale e Terapia cellulare

Roma, Italy

Istituto Clinico Humanitas - U.O. Ematologia

Rozzano, Italy

AOU di Sassari - Ematologia

Sassari, Italy

Nuovo Ospedale Civile di Sassuolo - Day Hospital Oncologico

Sassuolo, Italy

A.O.U. Citta della Salute e della Scienza di Torino - Ematologia Universitaria

Torino, Italy

Ospedale Ca Foncello - S.C di Ematologia

Treviso, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05934084

Related Trials

Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment

NCT065632451 location

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

NCT0233266817 locations

European Project for ctDNA Detection as a Biomarker for Non-invasive Therapy Monitoring in Paediatric Classical Hodgkin Lymphoma

NCT073568821 location

A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT053627737 locations

Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas

NCT042887262 locations